Results 211 to 220 of about 370,667 (257)
Some of the next articles are maybe not open access.
Tumor suppressor genes in urologic tumors
Urology, 1993During the last decade remarkable progress has been made in our understanding of the malignant phenotype. There is evidence that a series of genetic changes are involved in the conversion of a normal cell to a malignant one. These changes have been directly identified with mutations in various genes usually involved in cell growth and proliferation ...
J M, Wolff, F K, Habib
openaire +2 more sources
Annual Review of Biochemistry, 1993
THE ORIGINS OF THE CONCEPT OF TUMOR SUPPRESSOR GENES . . . . . . . 623 THE PROPERTIES OF ONCOGENES AND TUMOR SUPPRESSOR GENES . . 627 THE ONCOGENES OF THE DNA TUMOR VIRUSES TARGET THE MAJOR CELLULAR TUMOR SUPPRESSOR GENES 629 THE RETINOBLASTOMA SUSCEPTIBILITY GENE AND PROTEIN ........
openaire +2 more sources
THE ORIGINS OF THE CONCEPT OF TUMOR SUPPRESSOR GENES . . . . . . . 623 THE PROPERTIES OF ONCOGENES AND TUMOR SUPPRESSOR GENES . . 627 THE ONCOGENES OF THE DNA TUMOR VIRUSES TARGET THE MAJOR CELLULAR TUMOR SUPPRESSOR GENES 629 THE RETINOBLASTOMA SUSCEPTIBILITY GENE AND PROTEIN ........
openaire +2 more sources
Current Opinion in Genetics & Development, 2005
OVCA1, also known as DPH2L1, is a tumor suppressor gene associated with ovarian carcinoma and other tumors. Ovca1 homozygous mutant mice die at birth with developmental delay and cell-autonomous proliferation defects. Ovca1 heterozygous mutant mice are tumor-prone but rarely develop ovarian tumors.
Chun-Ming, Chen, Richard R, Behringer
openaire +2 more sources
OVCA1, also known as DPH2L1, is a tumor suppressor gene associated with ovarian carcinoma and other tumors. Ovca1 homozygous mutant mice die at birth with developmental delay and cell-autonomous proliferation defects. Ovca1 heterozygous mutant mice are tumor-prone but rarely develop ovarian tumors.
Chun-Ming, Chen, Richard R, Behringer
openaire +2 more sources
The Biomedical & Life Sciences Collection, 2016
A tumor suppressor gene is a type of cancer gene that is created by a loss-of-function mutation. In contrast to the activating mutations that generate oncogenic alleles from proto-oncogene precursors, tumor suppressor genes and the proteins they encode are functionally inactivated by mutations.
openaire +1 more source
A tumor suppressor gene is a type of cancer gene that is created by a loss-of-function mutation. In contrast to the activating mutations that generate oncogenic alleles from proto-oncogene precursors, tumor suppressor genes and the proteins they encode are functionally inactivated by mutations.
openaire +1 more source
BioEssays, 1990
AbstractThe retinoblastoma sensitivity protein (Rb) and the p53 gene product both appear to function as negative regulators of cell division or abnormal cellular growth in some differentiated cell types. Several types of cancers have been shown to be derived from cells that have extensively mutated both alleles of one or both of these genes, resulting ...
openaire +2 more sources
AbstractThe retinoblastoma sensitivity protein (Rb) and the p53 gene product both appear to function as negative regulators of cell division or abnormal cellular growth in some differentiated cell types. Several types of cancers have been shown to be derived from cells that have extensively mutated both alleles of one or both of these genes, resulting ...
openaire +2 more sources
Tumor suppressor genes and medulloblastoma
Journal of Neuro-Oncology, 1996Although primary intracranial neoplasms are the most common type of solid cancer in children, little is known about their etiology at the molecular genetic level. Recently, studies have shown that a class of genes known as tumor suppressors play an important role in the origin of several different types of human tumors, including those located in the ...
P H, Cogen, J D, McDonald
openaire +2 more sources
Annual Review of Genetics, 1990
INTRODUCTION . . . , ... ,", .. ", .... ,',', .... ", ..... , ...... " .... ,', .... ,' .. """, ... "" ....... '" 616 SOMATIC CELL HYBRID STUDIES . . . . . . . ... . . .. . . . . . . . . . . , 616 Specific Chromos,?me are Asso iated with Control of Tumorlgemc ExpressIOn . . . .
openaire +2 more sources
INTRODUCTION . . . , ... ,", .. ", .... ,',', .... ", ..... , ...... " .... ,', .... ,' .. """, ... "" ....... '" 616 SOMATIC CELL HYBRID STUDIES . . . . . . . ... . . .. . . . . . . . . . . , 616 Specific Chromos,?me are Asso iated with Control of Tumorlgemc ExpressIOn . . . .
openaire +2 more sources
Genes, Chromosomes and Cancer, 1998
The FRA3B at 3p14.2 is the most common of the constitutive aphidicolin-inducible fragile sites. Using independent approaches, four groups of investigators have cloned and characterized this fragile site. The results of these studies have revealed that the FRA3B differs from other heretofore cloned rare fragile sites. First, instability as manifested by
M M, Le Beau +6 more
openaire +2 more sources
The FRA3B at 3p14.2 is the most common of the constitutive aphidicolin-inducible fragile sites. Using independent approaches, four groups of investigators have cloned and characterized this fragile site. The results of these studies have revealed that the FRA3B differs from other heretofore cloned rare fragile sites. First, instability as manifested by
M M, Le Beau +6 more
openaire +2 more sources
Tumor Suppressor Genes in Ophthalmology
Survey of Ophthalmology, 1999Tumor suppressor genes have a diversity of functions, but they have in common the property of inhibiting neoplastic transformation. When they become inactivated, a constraint is removed that allows cells to grow inappropriately. Mutations in these genes are now thought to be the initiating events in most cancers.
openaire +2 more sources
2003
Recent advances in genetics, molecular biology, and molecular pharmacology have resulted in the development of molecularly targeted therapies. Targeting specific molecular pathways essential for the survival of cancer cells would personalize treatment with the potential to improve outcome and minimize toxicities.
Jack A, Roth, Susan F, Grammer
openaire +2 more sources
Recent advances in genetics, molecular biology, and molecular pharmacology have resulted in the development of molecularly targeted therapies. Targeting specific molecular pathways essential for the survival of cancer cells would personalize treatment with the potential to improve outcome and minimize toxicities.
Jack A, Roth, Susan F, Grammer
openaire +2 more sources